Daily News for Dealmakers
Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Source
Author: unknown
Strategic Investment: CVC Capital Partners targets €700 million fundraising for Genetic, a leading Italian pharmaceutical outsourcing company, to drive organic and inorganic growth. Industry...
Strategic Focus: The merger between AlloVir and Kalaris Therapeutics creates a biotech entity laser-focused on developing innovative treatments for retinal diseases like neovascular age-related...
Strategic Consolidation: AlloVir and Kalaris Therapeutics merge to create a biotech powerhouse focused on retinal disease treatments. Market Potential: The global retinal disease market is projected...
Strategic Acquisition: Boston Scientific's acquisition of Cortex, Inc. expands its electrophysiology portfolio with the OptiMap System, a diagnostic mapping solution for complex atrial fibrillation...